Table 2.
Site-specific 5-year cumulative incidence of recurrence and recurrence-free interval
| Overall (AC+LCNEC+SCLC)* (n=188) | Histologic subtype | STAS | ||||||
|---|---|---|---|---|---|---|---|---|
| AC (n=38) | LCNEC (n=93) | SCLC (n=57) | p | Absent (n=108) | Present (n=80) | p | ||
| 5-year CIR (any) | 37 (31, 45) | 37 (24, 57) | 40 (31, 51) | 33 (22, 48) | 0.7 | 24 (17, 34) | 54 (43, 66) | <0.001 |
| 5-year CIR (site-specific)¶ | ||||||||
| Liver | 11 (7, 17) | 20 (10, 39) | 5 (2, 13) | 15 (8, 28) | 0.020 | 8 (4, 15) | 15 (9, 26) | 0.098 |
| Brain | 10 (7, 16) | 0 (N/A) | 13 (8, 22) | 13 (6, 26) | 0.060 | 5 (2, 11) | 18 (11, 29) | 0.010 |
| Bone | 10 (7, 16) | 14 (6, 32) | 10 (5, 18) | 9 (4, 21) | 0.5 | 8 (4, 15) | 14 (8, 24) | 0.3 |
| Lymph node | 7 (4, 12) | 8 (3, 25) | 4 (2, 12) | 11 (5, 24) | 0.4 | 4 (1, 10) | 12 (6, 22) | 0.032 |
| Lung | 6 (3, 10) | 3 (0, 21) | 7 (3, 15) | 5 (2, 17) | 0.9 | 5 (2, 12) | 6 (3, 15) | 0.3 |
| Pleural/chest wall | 3 (2, 7) | 3 (0, 21) | 4 (2, 12) | 2 (0, 13) | 0.7 | 2 (0, 8) | 5 (2, 13) | 0.2 |
| Adrenal | 2 (1, 6) | 0 (N/A) | 1 (0, 8) | 5 (2, 17) | 0.14 | 0 (N/A) | 5 (2, 13) | 0.020 |
| Other | 3 (2, 7) | 6 (1, 24) | 3 (1, 10) | 2 (0, 13) | 0.8 | 3 (1, 9) | 4 (1, 12) | 1.0 |
| 5-year CIR by recurrence pattern | ||||||||
| Only locoregional | 6 (4, 12) | 6 (1, 23) | 8 (3, 17) | 5 (1, 20) | 0.8 | 6 (3, 14) | 7 (3, 17) | 0.8 |
| Only distant | 30 (24, 38) | 31 (18, 53) | 33 (24, 45) | 26 (16, 42) | 0.8 | 21 (14, 32) | 42 (32, 56) | 0.006 |
| Both | 5 (3, 10) | 3 (0, 23) | 4 (1, 11) | 9 (3, 23) | 0.6 | 2 (1, 10) | 8 (4, 18) | 0.027 |
| Recurrence-free interval# | ||||||||
| <1 year | 35 (19) | 2 (5) | 22 (24) | 11 (19) | — | 12 (11) | 23 (29) | — |
| ≥1 year | 37 (20) | 13 (34) | 16 (17) | 8 (14) | — | 16 (15) | 21 (26) | — |
#
Data are shown as percentage of 5-year cumulative incidence of recurrence (95% confidence interval) or number (raw %).
*
The typical carcinoid cohort is not included in prognostic analysis because of only 4 recurrences.
¶
Initial recurrence site (including overlap in patients with multiple recurrence sites at the initial recurrence) was analyzed. Significant p values are shown in bold. AC, atypical carcinoid; CI, confidence interval; CIR, cumulative incidence of recurrence; LCNEC, large cell neuroendocrine carcinoma; N/A, not applicable; SCLC, small cell lung carcinoma; STAS, spread through air spaces.